Technologies for producing platelet masses for regenerative medicine

Abstract

The development of regenerative medicine is to improve existing and to search for new tools for morphological and functional tissue repair, among which plasma or fi brin enriched with platelets (PRP and PRF) can be signifi cant. Autogenic platelet masses stimulate collagen synthesis, induce vascular growth, reduce pain, provide hemostasis, accelerate regeneration, reduce the risk of postoperative infectious and infl ammatory complications, and also have powerful osteoinductive properties. Due to the ability to produce the majority of growth factors, platelets can aff ect all stages of the infl ammatory-regenerative process, and therefore their biological products are of great importance in solving the problems of regenerative medicine. The technologies for obtaining PRP and PRF are based on centrifugation of blood, as a result of which its active components are concentrated in certain areas of the centrifuge. Blood sampling with or without an anticoagulant, as well as modifi cation of centrifugation protocols, allows to obtain various forms of platelet masses, such as a liquid, gel or clots. They are classifi ed, depending on the cellular content and architecture of fi brin, into several categories, namely: pure plasma enriched in platelets (P-PRP), plasma enriched in leukocytes and platelets (L-PRP); injectable fi brin enriched with platelets (i-PRF) and pure fi brin enriched with platelets (P-PRF), as well as fi brin enriched with white blood cells and platelets (L-PRF). The main diff erence in the manufacture of PRP compared to PRF is the use of anticoagulants and activators, as well as the possibility of using two-stage centrifugation. Platelet mass is used as an independent component mainly to stimulate the restoration of muscle tissue, to heal chronic wounds, to treat articular pathologies, and in combination with other materials, in particular to replace bone defects. The mechanisms of infl uence of each of the categories of platelet mass on tissue regeneration remains poorly understood. It is necessary to standardize the protocols for their preparation, taking into account the infl uence of additional substances, such as platelet activators or blood clotting and anticoagulants, as well as optimization of the methods for using each of the platelet mass forms.